The earliest therapy targeting tumor vasculature was the anti-vascular endothelial growth factor (anti-VEGF) agents, such as bevacizumab, which has been shown to improve the efficacy of traditional chemotherapy or immunotherapy for some solid tumors [112,113]. The gene discussed is VEGFA; the disease is neoplasm.